Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

This was the stock's fourth consecutive day of gains.

Back in 2020, the company announced it would give up the development of VX-814, a potential treatment for alpha-1 antitrypsin ...

Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Summit Therapeutics is poised for major success with its cancer immunotherapy ...

Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion. The program does not have an expiration date and can be discontinued at any time, the Boston-based ...

People need healthcare products and services regardless of what's happening with the economy. Which healthcare stocks could ...